GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-07-11| ChinaFunding

Zhiyi Biotech Finishes Series B Funding With $45 Million For Live Biotherapeutics

by Joy Lin
Share To

Guangzhou, China-based Zhiyi Biotech has raised $15 million in its B++ funding round, bringing the total amount of funds raised across B, B+, and B++ funding to $45 million. The latest round was joined by a syndicate of Chinese investors, including Qingkong SinoKing Capital, SDIC Venture Capital, and KIP. 

Zhiyi works to isolate and identify new functional strains of microorganisms and turn them into live biotherapeutic products, or LBPs. Its lead product, SK08, is undergoing a Phase 2 study in irritable bowel syndrome (IBS-D) that is expected to be completed this year. The company has also begun another Phase 1b/2 trial of SK08 combined with a PD-1 inhibitor for advanced solid tumors. Other pipeline products are undergoing IND filing to both the US FDA and China’s NMPA.  

Related article: Brii Biosciences Begins Marketing COVID-19 Antibody Cocktail Therapy in China

 

LBPs as Potential Cancer Treatments 

 

The active substance of SK08 is from a bacterial strain of Bacteroides fragilis, a common gut bacteria. Notably in 2019, SK08 became the first LBP in oncology to reach the clinic in China. Preclinical studies on SK08 suggest that the LBP may promote T-cell migration and proliferation, dendritic cell maturation and inflammation such as cytokine secretion in the tumor microenvironment. 

While LBPs are slowly gaining interest as a cancer treatment, drug developers must pay attention to the quality, safety and efficacy of their candidate. A concern is how the strain reaches the tumor, and the possibility of unwanted sepsis, infection, or inflammation. The strain must also be designed to be unable to transfer antibiotic resistance to other microbes. 

To ensure the purity of their LBPs, Zhiyi has established a platform system for strain selection, drug ability study, CMC study, and owns two commercial-scale plants for production.

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Pfizer-backed Flare Taps Caris To Boost Precision Oncology Pipeline
2023-04-17
Zenas Picks Up $118 Million To Advance Phase 3 For Autoimmune Candidate
2022-11-10
Lepu, HanX Scores China Approval For PD-1 Inhibitor
2022-07-27
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top